ArticleHaematologica2020
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Myelodysplastic Syndromes-Transformed Acute Myeloid Leukemia With Concurrent DEK::CAN Fusion Gene Positivity and WT1 Overexpression: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.) · 2026Review
- Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP).Bone marrow transplantation · 2026Article
- LncRNAiScience · 2025Article
- Article
- XPO1-dependency of DEK::NUP214 leukemia.Leukemia · 2025Article
- FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(Haematologica · 2024Article
- [Analysis of therapeutic effects of allogeneic hematopoietic stem cell transplantation in 12 patients with DEK-NUP214 fusion gene positive acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival.Haematologica · 2023Article
- Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.Annals of hematology · 2022Article
- Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.PLoS genetics · 2022Article
- Gilteritinib monotherapy as a transplant bridging option for high riskLeukemia research reports · 2022Article
- Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis.Cold Spring Harbor perspectives in medicine · 2021Review
- Advances in therapeutic options for newly diagnosed, high-risk AML patients.Therapeutic advances in hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 20 institutions in 5 countries.
Sabine KayserDepartment of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany s.kayser@dkfz-heidelberg.de.
Robert K HillsCardiff University School of Medicine, Cardiff, UK.
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew M BrunnerMassachusetts General Hospital, Boston, MA, USA.
Christine TerréLaboratory of Hematology, André Mignot Hospital, Le Chesnay, France.
Jörg WestermannDepartment of Hematology, Oncology and Tumor Immunology, Charité-University Medical Center, Campus Virchow Clinic, Berlin, Germany.
Kamal MenghrajaniLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Carole ShawClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Maria R BaerUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Michelle A ElliottDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Alexander E PerlDivision of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Zdeněk RáčilDepartment of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Jiri MayerDepartment of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Pavel Zak4 Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic.
Tomas SzotkowskiDepartment of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
Stéphane de BottonUniversité Paris-Saclay, Gustave Roussy Villejuif, France.
David GrimwadeDepartment of Medical & Molecular Genetics, King's College London, Faculty of Life Sciences and Medicine, London, UK.
Karin MayerMedical Clinic III for Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Roland B WalterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Alwin KrämerDepartment of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
Alan K BurnettCardiff University School of Medicine, Cardiff, UK.
Anthony D HoDepartment of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
Uwe PlatzbeckerMedical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
Christian ThiedeDepartment of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Gerhard EhningerDepartment of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Christoph RölligDepartment of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany.
Martin S TallmanLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
Elihu H EsteyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Carsten Müller-TidowDepartment of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.
Nigel H RussellDepartment of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Richard F SchlenkNCT Trial Center, National Center for Tumor Diseases, Heidelberg, Germany.
Mark J LevisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
University Hospital Carl Gustav Carus · DECardiff University · GBDana-Farber Cancer Institute · USUniversity Hospital Heidelberg · DEUniversity of Washington · USCharité - Universitätsmedizin Berlin · DECharles University · CZCornell University · USFred Hutch Cancer Center · USGerman Cancer Research Center · DEHeidelberg University · DEHôpital André Mignot · FRJohns Hopkins University · USKing's College London · GBMasaryk University · CZMassachusetts General Hospital · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USNational Center for Tumor Diseases · DENottingham University Hospitals NHS Trust · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MCancer Research UK 13371Cancer Research UK 16484NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA100632
Abstract
Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultCytarabineDisease-Free SurvivalHumansMiddle AgedRemission InductionRetrospective StudiesCytarabine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.